← Dashboard
Stock
REGN
REGENERON PHARMACEUTICALS, INC.Health CareBiotechnologyLatest close $6308 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
8
27 funds tracked
Ever held
12
Current + past
New this quarter
0
Exited this quarter
1
Marquee-fund ownership over time
Aug 13, 2013Nov 14, 2017Nov 15, 2021Nov 3, 2025
Now
8
This quarter's activity
New positions opened
None.
Positions exited
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Bridgewater Associates re-entered | Q3 2013 | 52Q | $242 | $630 | +160% |
| Renaissance Technologies | Q3 2024(8Q snapshot) | 7Q | $1124 | $630 | -44% |
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $1149 | $630 | -45% |
| D.E. Shaw | Q3 2024(8Q snapshot) | 7Q | $1149 | $630 | -45% |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $1149 | $630 | -45% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $1149 | $630 | -45% |
| Point72 Asset Management re-entered | Q3 2024(8Q snapshot) | 7Q | $1149 | $630 | -45% |
| Two Sigma Investments | Q4 2024(8Q snapshot) | 6Q | $777 | $630 | -19% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Scion Asset Management | Q3 2025 | Q4 2025 | → $641 | +14% |
| Viking Global Investors 3× in & out | Q2 2025 | Q3 2025 | → $563 | -3% |
| Maverick Capital 3× in & out | Q1 2024 | Q2 2024 | → $970 | +3% |
| Duquesne Family Office 2× in & out | Q3 2020 | Q1 2021 | → $477 | -22% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at REGENERON PHARMACEUTICALS, INC.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
Filings · last 30d
1
Filings · last 90d
6
Total on file
642
Recent SEC buffer
Most recent
May 4, 2026
30d / 90d windows measured from May 4, 2026 — the most recent Form 4 on file — not from today.
- Form 40001187443-26-000008May 4, 2026
- Form 40001104659-26-039613Apr 3, 2026
- Form 40001187443-26-000006Mar 3, 2026
- Form 40001681643-26-000004Feb 23, 2026
- Form 40002009236-26-000001Feb 11, 2026
- Form 40001187443-26-000004Feb 11, 2026
- Form 40001683607-26-000008Jan 8, 2026
- Form 40001681643-26-000002Jan 6, 2026
- Form 40001423419-26-000001Jan 6, 2026
- Form 40001225471-26-000002Jan 6, 2026
- Form 40001992352-26-000003Jan 6, 2026
- Form 40001578200-26-000002Jan 6, 2026
- Form 40001225474-26-000002Jan 6, 2026
- Form 40001187443-26-000002Jan 6, 2026
- Form 40001197018-26-000002Jan 6, 2026
Showing 15 of 642 recent Form 4 filings. Browse all on EDGAR ↗
Fundamentals
XBRL · REGENERON PHARMACEUTICALS, INC.Annual figures sourced directly from REGENERON PHARMACEUTICALS, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Revenue
$14.34B
FY2025+1% YoY
Net income
$4.5B
FY2025+2% YoY
EPS (diluted)
$41.48
FY2025+8% YoY
Free cash flow(?)
$4.98B
FY2025+13% YoY
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for REGENERON PHARMACEUTICALS, INC. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 10-QQuarterly reportApr 29, 2026
- 8-KMaterial eventApr 29, 2026
- DEF 14ADEFINITIVE PROXY STATEMENTApr 24, 2026
- 8-KFORM 8-KApr 8, 2026
- 10-KAnnual reportFeb 4, 2026
- 8-KMaterial eventJan 30, 2026
- 8-KFORM 8-KJan 12, 2026
- 10-QQuarterly reportOct 28, 2025
- 8-KMaterial eventOct 28, 2025
- 8-KFORM 8-KOct 6, 2025
- 10-QQuarterly reportAug 1, 2025
- 8-KMaterial eventAug 1, 2025
- 8-KFORM 8-KJun 18, 2025
- 10-QQuarterly reportApr 29, 2025
- 8-KMaterial eventApr 29, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Scion Asset Management | Q3 2025 | Q4 2025 | $564 | $641 | +14% |
| Point72 Asset Management | Q3 2025 | open | $564 | $630 | +12% |
| Viking Global Investors | Q2 2025 | Q3 2025 | $581 | $563 | -3% |
| Two Sigma Investments | Q4 2024 | open | $777 | $630 | -19% |
| Viking Global Investors | Q4 2024 | Q1 2025 | $776 | $668 | -14% |
| Citadel Advisors | Q3 2024 | open | $1149 | $630 | -45% |
| D.E. Shaw | Q3 2024 | open | $1149 | $630 | -45% |
| AQR Capital Management | Q3 2024 | open | $1149 | $630 | -45% |
| Millennium Management | Q3 2024 | open | $1149 | $630 | -45% |
| Point72 Asset Management | Q3 2024 | Q4 2024 | $1149 | $777 | -32% |
| Renaissance Technologies | Q3 2024 | open | $1124 | $630 | -44% |
| Maverick Capital | Q1 2024 | Q2 2024 | $940 | $970 | +3% |
| Maverick Capital | Q4 2021 | Q1 2022 | $642 | $618 | -4% |
| Bridgewater Associates | Q3 2021 | open | $620 | $596 | -4% |
| Maverick Capital | Q4 2020 | Q1 2021 | $555 | $477 | -14% |
| Duquesne Family Office | Q3 2020 | Q1 2021 | $608 | $477 | -22% |
| Bridgewater Associates | Q3 2019 | Q1 2020 | $302 | $396 | +31% |
| Bridgewater Associates | Q2 2018 | Q2 2019 | $298 | $302 | +1% |
| Duquesne Family Office | Q4 2017 | Q1 2018 | $382 | $328 | -14% |
| Bridgewater Associates | Q4 2017 | Q1 2018 | $390 | $322 | -18% |
| Bridgewater Associates | Q2 2016 | Q3 2016 | $366 | $412 | +12% |
| Bridgewater Associates | Q3 2015 | Q1 2016 | $562 | $364 | -35% |
| Bridgewater Associates | Q3 2014 | Q2 2015 | $335 | $487 | +45% |
| Viking Global Investors | Q2 2014 | Q1 2015 | $287 | $401 | +40% |
| Bridgewater Associates | Q3 2013 | Q4 2013 | $242 | $275 | +13% |
Caveats
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.